CONNECT WITH US
Tech

Tech

Thyrocare Q2 Profit Slips 68% YoY To ₹15 Cr Due To ₹45 Cr Exceptional Expense

Inc42 - All News logo

Published on

Add as a preferred source on Google
Thyrocare Q2 Profit Slips 68% YoY To ₹15 Cr Due To ₹45 Cr Exceptional Expense

PharmEasy-backed Thyrocare’s net profit for the September quarter (Q2 FY27) slumped 68.2% year-on-year (YoY) to ₹15.2 Cr from ₹47.8 Cr in the year-ago period. This also marks a 70% dip from ₹51.3 Cr profit in the previous quarter.

The company’s bottom line was weighed by an exceptional impairment loss of about ₹45 Cr on its investment in radiology and diagnostic-imaging subsidiary Nueclear Healthcare Limited (NHL). 

The company’s board approved the sale of its entire stake in the wholly owned subsidiary to Trovera Healthcare for about ₹141.4 Cr on September 21. The impairment costs come at the behest of the definitive term sheet for the proposed sale of the business.

“Thyrocare has issued a postal ballot seeking shareholders’ approval for the proposed divestment of its Nuclear Imaging business, enabling the company to sharpen its focus and allocate capital towards its Pathology business, which offers a stronger growth trajectory, higher margins and better return on capital employed (ROCE),” the company said in a statement.

Meanwhile, the company’s operating revenue rose 25% YoY and 13% QoQ to ₹270.8 Cr in the quarter. In this, revenue from diagnostic testing services rose 26% YoY to ₹256.7 Cr, while revenue from imaging services declined 5% to ₹13.6 Cr.

Including other income of ₹3.6 Cr, total income for the quarter stood at ₹274.4 Cr.

Meanwhile, expenses for the quarter stood at ₹196.6 Cr. Tax expense for the quarter stood at ₹18.4 Cr. 

8 Cr. 3 Cr.



Source link
Related Topics:Tech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.